GPSM2 and invasive breast carcinoma: In Figure 3A, GPSM2 was positively correlated with DYNC1I1 in several cancers, such as bladder urothelial carcinoma (BLCA, R = 0.16, p = 0.0016), breast invasive carcinoma (BRCA, R = 0.28, p = 0), glioblastoma multiforme (GBM, R = 0.27, p < 0.001) and prostate adenocarcinoma (PRAD, R = 0.33, p < 0.001).